Weixiao Han

1.7k total citations · 1 hit paper
7 papers, 988 citations indexed

About

Weixiao Han is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Weixiao Han has authored 7 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 5 papers in Cardiology and Cardiovascular Medicine and 4 papers in Epidemiology. Recurrent topics in Weixiao Han's work include Viral gastroenteritis research and epidemiology (5 papers), Viral Infections and Immunology Research (5 papers) and Respiratory viral infections research (4 papers). Weixiao Han is often cited by papers focused on Viral gastroenteritis research and epidemiology (5 papers), Viral Infections and Immunology Research (5 papers) and Respiratory viral infections research (4 papers). Weixiao Han collaborates with scholars based in China. Weixiao Han's co-authors include Kai Chu, Fengcai Zhu, Changgui Li, Xiangxi Wang, Yaling Hu, Zhen Chen, Yan Song, Yanjun Zhang, Weidong Yin and Minnan Yang and has published in prestigious journals such as The Lancet Infectious Diseases, International Journal of Infectious Diseases and Expert Review of Vaccines.

In The Last Decade

Weixiao Han

7 papers receiving 960 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

2020 937 citations Yanjun Zhang, Gang Zeng et al. The Lancet Infectious Diseases profile →

Peers

Weixiao Han

ID

HEALT

MB

IMMUN

MS

Carina C. D. Joe United Kingdom

Mimi M. Hou United Kingdom

Minnan Yang China

Thomas A. Rawlinson United Kingdom

Amy Flaxman United Kingdom

Katie E. Flight United Kingdom

Carmit Rubin Israel

Saied Ghorbani Iran

Omri Bodenheimer Israel

Carina C. D. Joe United Kingdom

Weixiao Han

728 ×0.9

ID

280 ×0.9

HEALT

110 ×1.0

MB

120 ×1.2

IMMUN

84 ×0.9

MS

Citations per year, relative to Weixiao Han Weixiao Han (= 1×) peers Carina C. D. Joe

Countries citing papers authored by Weixiao Han

Since Specialization

Citations

This map shows the geographic impact of Weixiao Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixiao Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixiao Han more than expected).

Fields of papers citing papers by Weixiao Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weixiao Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixiao Han. The network helps show where Weixiao Han may publish in the future.

Co-authorship network of co-authors of Weixiao Han

This figure shows the co-authorship network connecting the top 25 collaborators of Weixiao Han. A scholar is included among the top collaborators of Weixiao Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weixiao Han. Weixiao Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Jiang, Deyu, Weixiao Han, Zhiqiang Xie, et al.. (2023). Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. International Journal of Infectious Diseases. 130. 20–27. 2 indexed citations

2.

Zheng, Yan, Weixiao Han, Ya Jiang, et al.. (2022). Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial. Vaccines. 10(2). 254–254. 2 indexed citations

3.

Chu, Kai, Weixiao Han, Deyu Jiang, et al.. (2021). Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses. Expert Review of Vaccines. 20(6). 761–767. 4 indexed citations

4.

Zhang, Yanjun, Gang Zeng, Hongxing Pan, et al.. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21(2). 181–192. 937 indexed citations breakdown →

5.

Hu, Yuemei, Kangwei Xu, Weixiao Han, et al.. (2019). Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China. Open Forum Infectious Diseases. 6(10). 8 indexed citations

6.

Hu, Yuemei, Gang Zeng, Kai Chu, et al.. (2018). Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Human Vaccines & Immunotherapeutics. 14(6). 1517–1523. 27 indexed citations

7.

Huang, Lili, Ling Wang, Yuansheng Hu, et al.. (2018). A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly. Human Vaccines & Immunotherapeutics. 15(1). 249–255. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact